KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases (2016)

Historic Capital Leases for Rigel Pharmaceuticals (RIGL) over the last 5 years, with Q4 2016 value amounting to $238000.0.

  • Rigel Pharmaceuticals' Capital Leases fell 9312.14% to $238000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $238000.0, marking a year-over-year decrease of 9312.14%. This contributed to the annual value of $238000.0 for FY2016, which is 9312.14% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Capital Leases stood at $238000.0 for Q4 2016, which was down 9312.14% from $1.1 million recorded in Q3 2016.
  • Rigel Pharmaceuticals' Capital Leases' 5-year high stood at $6.5 million during Q4 2014, with a 5-year trough of $238000.0 in Q4 2016.
  • Moreover, its 3-year median value for Capital Leases was $3.5 million (2015), whereas its average is $3.4 million.
  • Its Capital Leases has fluctuated over the past 5 years, first crashed by 4648.93% in 2015, then plummeted by 9312.14% in 2016.
  • Rigel Pharmaceuticals' Capital Leases (Quarter) stood at $6.5 million in 2014, then crashed by 46.49% to $3.5 million in 2015, then crashed by 93.12% to $238000.0 in 2016.
  • Its Capital Leases was $238000.0 in Q4 2016, compared to $1.1 million in Q3 2016 and $1.9 million in Q2 2016.